Changes to the TSCA After 8 Years Webinar
Bergeson Campbell Webinar focuses on TSCA implementation challenges and accomplishments since the enactment of the Lautenberg Act amendments and where it stands now.
Source: natlawreview.com
📰 Risk Evaluation News
Page 2 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
Avadel to Present Data on Lumryz for Narcolepsy at SLEEP 2024
At SLEEP 2024, Avadel will present new data on Lumryz, the first extended-release, once-nightly formulation of sodium oxybate for narcolepsy.
United States Michaelj Thorpy Maggie Lavender Jennifer Gudeman Drug Administration Wake Disorders Center At Montefiore
Source: sleepreviewmag.com
United States - Securities - Northern District Of California Dismisses With Prejudice Putative Class Action Against Pharmaceutical Company
On May 7, 2024, Judge Beth Labson Freeman of the United States District Court for the Northern District of California dismissed with prejudice a putative shareholders' class action against a pharmaceutical company and certain of its executives...
United States Beth Labson Freeman Company Risk Evaluation Securities Exchange District Court Acelrx Pharms Inc
Source: mondaq.com
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical benefit with median duration of response not reached and the majority of responders in...
United Kingdom Hemophagocytic Lymphohistiocytosis Meghan Gutierrez Bryan Campbell Bristol Myers Squibb John Cunningham
Source: marketscreener.com
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | Business
PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2024--
United Kingdom John Cunningham Hemophagocytic Lymphohistiocytosis Meghan Gutierrez Bryan Campbell Bristol Myers Squibb
Source: valdostadailytimes.com
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | Region
PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2024--
United Kingdom John Cunningham Bristol Myers Squibb Meghan Gutierrez Bryan Campbell Hemophagocytic Lymphohistiocytosis
Source: eagletribune.com
FDA Broadens Breyanzi's Follicular Lymphoma Indication
The overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
Source: medscape.com
FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma
FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.
San Diego United States Meghan Gutierrez Bristol Myers Squibb Marial Palomba Follicular Lymphoma Foundation
Source: ajmc.com
Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular Lymphoma
Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
Saurabh Dahiya Stanford University School Of Medicine Cell Therapy Division Stanford University School Cancer Cell Therapy Risk Evaluation
Source: onclive.com
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan...
Source: marketscreener.com